

Literaturverzeichnis

1. National Institute for Health and Care Excellence. Overview | COVID-19 rapid guideline: managing the long-term effects of COVID-19 | Guidance | NICE; 2020. Available from: URL: <https://www.nice.org.uk/guidance/ng188>.
2. Reisinger EC, Geerdes-Fenge H, Wossidlo C, Arndt H. Long/Post-COVID – eine interdisziplinäre Herausforderung. *Rofo* 2025; 197(12):1388–94.
3. Geerdes-Fenge HF, Reisinger EC, Arndt H. Pulmonary Artery Embolism in COVID-19 Despite Thrombosis Prophylaxis. *Dtsch Arztebl Int* 2020; 117(17):297.
4. Trautmann A. Core features and inherent diversity of post-acute infection syndromes. *Front Immunol* 2025; 16:1509131.
5. Lundberg-Morris L, Leach S, Xu Y, Martikainen J, Santosa A, Gisslén M et al. COVID-19 vaccine effectiveness against post-COVID-19 condition among 589 722 individuals in Sweden: population based cohort study. *BMJ* 2023; 383:e076990.
6. Bahmer T, Borzikowsky C, Lieb W, Horn A, Krist L, Fricke J et al. Severity, predictors and clinical correlates of Post-COVID syndrome (PCS) in Germany: A prospective, multi-centre, population-based cohort study. *EClinicalMedicine* 2022; 51:101549.
7. Bell DS. The doctor's guide to chronic fatigue syndrome : understanding, treating, and living with CFIDS / David S. Bell. Reading, Mass.: Addison-Wesley Pub. Co; 1995.
8. Klok FA, Boon GJAM, Barco S, Endres M, Geelhoed JJM, Knauss S et al. The Post-COVID-19 Functional Status scale: a tool to measure functional status over time after COVID-19. *Eur Respir J* 2020; 56(1).
9. National Academies Press (US). Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. Washington (DC); 2015.
10. Wong TL, Weitzer DJ. Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)-A Systemic Review and Comparison of Clinical Presentation and Symptomatology. *Medicina (Kaunas)* 2021; 57(5).
11. Blitshteyn S. Autoimmune markers and autoimmune disorders in patients with postural tachycardia syndrome (POTS). *Lupus* 2015; 24(13):1364–9.
12. Björnson M, Wijnbladh K, Törnberg A, Svensson-Raskh A, Svensson A, Ståhlberg M et al. Prevalence and Clinical Impact of Postural Orthostatic Tachycardia Syndrome in Highly Symptomatic Long COVID. *Circ Arrhythm Electrophysiol* 2025; 18(10):e013629.
13. Ormiston CK, Świątkiewicz I, Taub PR. Postural orthostatic tachycardia syndrome as a sequela of COVID-19. *Heart Rhythm* 2022; 19(11):1880–9.
14. Panagea E, Messinis L, Petri MC, Liampas I, Anyfantis E, Nasios G et al. Neurocognitive Impairment in Long COVID: A Systematic Review. *Arch Clin Neuropsychol* 2025; 40(1):125–49.

15. Hampshire A, Azor A, Atchison C, Trender W, Hellyer PJ, Giunchiglia V et al. Cognition and Memory after COVID-19 in a Large Community Sample. *N Engl J Med* 2024; 390(9):806–18.
16. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc* 2005; 53(4):695–9.
17. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Leitlinien-Details Registernummer 020 - 027 S1-Leitlinie Long/ Post-COVID; 2024. Available from: URL: <https://register.awmf.org/de/leitlinien/detail/020-027>.
18. Fu Q, Levine BD. Exercise and non-pharmacological treatment of POTS. *Auton Neurosci* 2018; 215:20–7.
19. Rudofker EW, Parker H, Cornwell WK. An Exercise Prescription as a Novel Management Strategy for Treatment of Long COVID. *JACC Case Rep* 2022; 4(20):1344–7.
20. Vassiliou VS, Tsampasian V, Luchian ML, D'Ascenzi F, D'Ascenzo F, Dweck MR et al. Cardiovascular disease prevention and management in COVID-19: a clinical consensus statement of the European Association of Preventive Cardiology, the European Association of Cardiovascular Imaging, the Association of Cardiovascular Nursing & Allied Professions, the European Association of Percutaneous Cardiovascular Interventions, and the Heart Failure Association of the ESC. *Eur J Prev Cardiol* 2025.
21.
(https://www.bfarm.de/SharedDocs/Downloads/DE/Arzneimittel/Zulassung/ZulRelThemen/LongCOVID/bewertung-ivabradin.pdf?__blob=publicationFile - Google Suche; 2026 [cited 2026 Feb 27]. Available from: URL: https://www.google.com/search?client=firefox-b-d&q=Prozent28httpsProzent3AProzent2FProzent2Fwww.bfarm.deProzent2FSharedDocsProzent2FDownloadsProzent2FDEProzent2FArzneimittelProzent2FZulassungProzent2FZulRelThemenProzent2FLongCOVIDProzent2Fbewertung-ivabradin.pdfProzent3F__blobProzent3DpublicationFile.
22. Löffler C, Daubmann A, Endlicher D, Galchenko V, Jendyk R, Reisinger EC et al. Patient-centred interprofessional teleconsultation for post-viral symptom complexes in German primary care-protocol for the cluster-randomised controlled COVI-Care M-V trial. *BMC Health Serv Res* 2025; 25(1):1194.
23. Fricke F, Mai F, Wossidlo C, Steinbeck F, Bergmann-Ewert W, Kordt M et al. Transcriptome analysis of classical blood cells reveals downregulation of pro-inflammatory genes in the classical monocytes of long COVID patients. *Front Immunol* 2025; 16:1710783.
24. Mai F, Bergmann W, Reisinger EC, Müller-Hilke B. The varying extent of humoral and cellular immune responses to either vector- or RNA-based SARS-CoV-2 vaccines persists for at least 18 months and is independent of infection. *J Virol* 2024; 98(4):e0191223.

25: <https://doi.org/10.1007/s15010-026-02914-8>

26. Steinmetz A, Gross S, Lehnert K, Lückner P, Friedrich N, Nauck M et al. Longitudinal Clinical Features of Post-COVID-19 Patients-Symptoms, Fatigue and Physical Function at 3- and 6-Month Follow-Up. J Clin Med 2023; 12(12).